The mission of the UAB CFAR is to support UAB investigators in the conduct of multidisciplinary, cutting edge research in the prevention, pathogenesis, therapeutics, clinical care, and psychosocial manifestations of HIV and related disorders in the community, within the US and around the world. For 25 years, the Center has played a vital role in supporting research activities of its members that have led to paradigm-shifting discoveries, including: the discovery of HIV-1 quasi-species diversity, detection of HIV-1 RNA in plasma, viral dynamics in acute and chronic infection, first-in-human phase 1 clinical studies of 7 currently approved therapies, the zoonotic origins of HIV-1, and the direct use of outcomes research data to inform clinical practice. Strategic planning activities have focused our scientific agenda over the next 5 years to address: HIV pathogeneses, the natural history of HIV in the treatment era, drug discovery, and prevention. The objectives of the CFAR reflect this modern agenda and further our commitment to innovative, multidisciplinary AIDS research, including: 1. Provision of a central institutional focus for HIV/AIDS research activities that emphasize effective communication and collaboration among CFAR members and the wider HIV/AIDS research community. 2. Enhancement of productivity of ongoing research programs by encouraging interdisciplinary research and by providing critical shared resource facilities and administrative and fiscal management support to Center investigators. 3. Use of robust strategic planning methods to identify new research opportunities and priorities that align with existing CFAR programs and foster new research programs where none are in existence but where faculty interest and University capacity is evident. 4. To stimulate the entry of junior and established faculty into HIV/AIDS research programs through mentoring programs for young investigators and by a peer-reviewed Developmental Grants Program. 5. To stimulate faculty recruitment and program development in areas that reflect the ongoing evolution of HIV/AIDS research in Alabama, the United States, and around the world. The success of the UAB CFAR in stimulating HIV/AIDS research is reflected in the growth in extramural funding from $6.0 million in 1988 to over $86 million currently, in the recruitment of more than 24 HIV/AIDS investigators since 2009, high profile publications, and in the garnering of outstanding Institutional support. .

Public Health Relevance

The UAB CFAR will stimulate and facilitate HIV/AIDS research that has high local, national, and international impact and in so doing will promote the NIH priorities of innovation and effectiveness in AIDS treatment and prevention

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
2P30AI027767-26
Application #
8682179
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Namkung, Ann S
Project Start
Project End
Budget Start
Budget End
Support Year
26
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Salazar-Gonzalez, Jesus F; Salazar, Maria G; Tully, Damien C et al. (2016) Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathog Immun 1:129-153
Abedini-Nassab, Roozbeh; Joh, Daniel Y; Van Heest, Melissa et al. (2016) Magnetophoretic Conductors and Diodes in a 3D Magnetic Field. Adv Funct Mater 26:4026-4034
Dalecki, Alex G; Malalasekera, Aruni P; Schaaf, Kaitlyn et al. (2016) Combinatorial phenotypic screen uncovers unrecognized family of extended thiourea inhibitors with copper-dependent anti-staphylococcal activity. Metallomics 8:412-21
Pettit, April C; Mendes, Adell; Jenkins, Cathy et al. (2016) Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 72:572-8
Friedman, Gregory K; Moore, Blake P; Nan, Li et al. (2016) Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 18:227-35
Demark-Wahnefried, Wendy; Nix, Jeffery W; Hunter, Gary R et al. (2016) Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for BMC Cancer 16:61
Merlin, Jessica S; Tamhane, Ashutosh; Starrels, Joanna L et al. (2016) Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV. AIDS Behav 20:687-98
Khan, Shahzada; Woodruff, Erik M; Trapecar, Martin et al. (2016) Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication. J Exp Med 213:2913-2929
Kumar, Ashish; Zhang, Jennifer; Tallaksen-Greene, Sara et al. (2016) Allelic series of Huntington's disease knock-in mice reveals expression discorrelates. Hum Mol Genet 25:1619-36
Qin, Hongwei; Buckley, Jessica A; Li, Xinru et al. (2016) Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. J Neurosci 36:5144-59

Showing the most recent 10 out of 784 publications